“Cancer care is the single most rapidly increasing component of US healthcare spending. More than 80% of that cancer care, including immunotherapy and chemotherapy, takes place in outpatient clinics,” said James Mitchell, MD, founder and CEO of Oncodisc, Inc. “We are pleased to work with the NSF on this important remote patient care technology to benefit the 17 million global patients diagnosed with cancer each year. Among the first to benefit will be the 9.8 million that require first-line chemotherapy and 7.4 million that are eligible for immunotherapy.”
“This funding will enable us to advance our AI-embedded intelligent implantable technology and support our mission to improve personalized cancer care through remote detection of changes in patient health status and streamlining doctor-patient communication. Our technology is applicable to other chronic diseases as well,” said Dr. Mitchell.